Problemi correnti
Il danno epatico da farmaci nel bambino
Drug-induced liver injury in childhood
Giuseppe Maggiore1, Silvia Nastasio1, Francesco Cirillo2, Marco Sciveres2
1Dipartimento di Medicina della Procreazione e dell’Età Evolutiva, Divisione di Pediatria, Azienda Ospedaliero-Universitaria Pisana, Ospedale Universitario Santa Chiara, Pisa
2Epatologia e Trapianto di Fegato Pediatrico UPMC - Ismett, Palermo
Ottobre 2012 - pagg. 508 -513
Abstract
Drug-induced liver injury (DILI) is the most common drug adverse event. Although DILI in
paediatric age is relatively rare, it accounts for 20% of acute liver failure. Pathogenetic mechanisms
are mostly idiosyncratic and therefore unpredictable and they mimic all forms of
acute and chronic hepatobiliary diseases. Diagnosis can be difficult and a high degree of
suspicion should be maintained. The most common drugs leading to DILI are acetaminophen,
with a dose-dependent liver toxicity, anti-tuberculosis drugs, central nervous system
agents, and anti-neoplastic drugs. Recently synthetic psychoactive drugs (Ecstasy) and
herbal and dietary supplements have an increasing role in adolescent DILI.
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Bibliografia
1. Maggiore G. Approccio clinico al bambino
con enzimi epatici elevati, “quasi” vent’anni
dopo… Medico e Bambino 2010;29:21-32.
2. Squires RH Jr, Shneider BL, Bucuvalas J, et
al. Acute liver failure in children: the first 348
patients in the Pediatric Acute Liver Failure
Study Group. J Pediatr 2006;148:652-8.
3. Darven TJ, James LP, Hinson JA, et al. Measurement
of serum acetaminophen-protein
adducts in patients with acute liver failure. Gastroenterology
2006;130:687-94.
4. Khandelwal N, James LP, Sanders C, Larson
AM, Lee WM; Acute Liver Failure Study
Group. Unrecognized acetaminophen toxicity
as a cause of indeterminate acute liver failure.
Hepatology 2011;53:567-76.
5. James LP, Alonso EM, Hynan LS, et al.; Pediatric
Acute Liver Failure Study Group. Detection
of acetaminophen protein adducts in
children with acute liver failure of indeterminate
cause. Pediatrics 2006;118:e676-e681.
6. Savino F, Lupica MM, Tarasco V, Locatelli E,
Garazzino S, Tovo PA. Fulminant hepatitis after
10 days of acetaminophen treatment at recommended
dosage in an infant. Pediatrics
2011;127:494-7.
7. Ranganathan SS, Sathiadas MG, Sumanasena
S, Fernandopulle M, Lambadusuriya SP,
Fernandopulle BMR. Fulminant hepatic failure
and paracetamol overuse with therapeutic
intent in febrile children. Indian J Pediatr
2006;73:871-5.
8. Dart RC, Bailey E. Does therapeutic use of
acetaminophen cause acute hepatic failure?
Pharmacotherapy 2007;27:1219-30.
9. Lavonas EJ, Reynolds KM, Dart RC. Therapeutic
acetaminophen is not associated with
liver injury in children: a systematic review.
Pediatrics 2010;126:1430-44.
10. Kortsalioudaki C, Taylor RM, Cheeseman
P, Bansai S, Mieli Vergani G. Safety and efficacy
of N-acetylcysteine in children with nonacetaminophen-
induced acute liver failure. Liv
Transplant 2008;14:25-30.
11. Bell LN, Chalasani N. Epidemiology of
idiosyncratic drug-induced liver injury. Semin
Liver Dis 2009;29:337-47.
12. Uetrecht J. Idiosyncratic drug reactions:
current understanding. Annu Rev Pharmacol
Toxicol 2007;47:513-39.
13. Lammert C, Einarsson S, Saha C, Niklasson
A, Bjornsson E, Chalasani N. Relationship
between daily dose of oral medications and
idiosyncratic drug-induced liver injury: search
for signals. Hepatology 2008;47:2003-9.
14. Lammert C, Bjornsson E, Niklasson A,
Chalasani N. Oral medications with significant
hepatic metabolism at higher risk for hepatic
adverse events. Hepatology 2010;51:615-20.
15. Chalasani N, Fontana RJ, Bonkovski HL,
et al.; Drug Induced Liver Injury Network.
Causes, clinical features and outcomes from
a prospective study of drug-induced liver
injury in the United States. Gastroenterology
2008;135:1924-34.
16. Tujios S, Fontana RJ. Mechanisms of druginduced
liver injury: from bedside to bench.
Nat Rev Gastroenterol Epatol 2011;8:202-11.
17. Stewart JD, Horvath R, Baruffini E, et al.
Polymerase gene POLG determinates the risk
of sodium valproate-induced liver toxicity.
Hepatology 2010;52:1791-6.
18. Molleston JP, Fontana RJ, Lopez MJ, Kleiner
DE, Gu J, Chalasani N; Drug-Induced Liver
Injury Network. Characteristics of idiosyncratic
drug-induced liver injury in children:
results from the DILIN prospective
study. J Pediatr Gastroenterol Nutr 2011;53:
182-9.
19. Devarbhavi H, Karanth D, Prasanna KS,
Adarsh CK, Patil M. Drug-Induced liver injury
with hypersensitivity features has a better outcome:
a single-center experience of 39 children
and adolescents. Hepatology 2011;54:
1344-50.
20. Murray KF, Hadzic N, Wirth S, Basset M,
Kelly D. Drug-related hepatotoxicity and liver
failure. J Pediatr Gastroenterol Nutr 2008;47:
395-405.
21. Rivkees SA, Mattison DR. Ending
propylthiouracil-induced liver failure in children.
N Engl J Med 2009;360:1574-5.
22. Malozowski S, Chiesa A. Propylthiouracilinduced
hepatotoxicity and death. Hopefully,
never more. J Clin Endocrinol Metab 2010;
95:3161-3.
Corrispondenza: giuseppe.maggiore@med.unipi.it